BlackRock’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-83,822
| Closed | -$49.5K | – | 5534 |
|
|
2024
Q4 | $49.5K | Buy |
83,822
+301
| +0.4% | +$209 | ﹤0.01% | 4952 |
|
|
2024
Q3 | $65.9K | Buy |
83,521
+24,011
| +40% | +$24K | ﹤0.01% | 4750 |
|
|
2024
Q2 | $75.6K | Buy |
59,510
+22,384
| +60% | +$29.6K | ﹤0.01% | 4769 |
|
|
2024
Q1 | $51.6K | Sell |
37,126
-11,318
| -23% | -$18.7K | ﹤0.01% | 4862 |
|
|
2023
Q4 | $77K | Buy |
48,444
+48,082
| +13,282% | +$61.3K | ﹤0.01% | 4879 |
|
|
2023
Q3 | $514 | Hold |
362
| – | – | ﹤0.01% | 5353 |
|
|
2023
Q2 | $576 | Hold |
362
| – | – | ﹤0.01% | 5423 |
|
|
2023
Q1 | $304 | Hold |
362
| – | – | ﹤0.01% | 5502 |
|
|
2022
Q4 | $514 | Hold |
362
| – | – | ﹤0.01% | 5666 |
|
|
2022
Q3 | $1K | Hold |
362
| – | – | ﹤0.01% | 5776 |
|
|
2022
Q2 | $1K | Sell |
362
-17,841
| -98% | -$43.2K | ﹤0.01% | 5827 |
|
|
2022
Q1 | $58K | Buy |
18,203
+4,352
| +31% | +$15.2K | ﹤0.01% | 5394 |
|
|
2021
Q4 | $51K | Buy |
13,851
+717
| +5% | +$4.06K | ﹤0.01% | 5399 |
|
|
2021
Q3 | $88K | Buy |
13,134
+2,290
| +21% | +$17.9K | ﹤0.01% | 5171 |
|
|
2021
Q2 | $111K | Buy |
+10,844
| New | +$90.8K | ﹤0.01% | 5019 |
|
BlackRock's CYTH Position: Q1 2025 in Review
BlackRock sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 83,822 shares — an estimated $49.5K sold.
BlackRock first reported a position in CYTH in Q2 2021 and held it in 15 quarters. The position peaked at $111K in Q2 2021. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- BlackRock reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- BlackRock sold 83,822 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $49.5K.
- BlackRock first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
- BlackRock's Cyclo Therapeutics, Inc. Common Stock position peaked at $111K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.